Oscar Tahuahua
@OscarTahuahua
Followers
1K
Following
4K
Media
239
Statuses
1K
Medical Oncologist @INCanMX | Thorac. fellow | #Immunotherapy & molecular target-believer | #OncoAlertAF | Op my own
Ciudad de México
Joined April 2020
RT @OncoAlert: The OncoAlert WEEKLY RoundUp 🚨 .Covering the TOP of the week July 25-31, 2025 . 👉REGISTER at OR….
0
8
0
AGEO study 🇫🇷: ICIs in MSI/dMMR biliary tract cancer. Retrospective (n=48). MSI/dMMR BTC rare (2–5%). Actionable drivers in 33%: IDH1, FGFR2/3, BRAF, HER2. 🌟mOS 40.9 mo, mPFS 11.2 mo, 3y OS 54% (vs 12.8 mo TOPAZ-1). 🔺MSI testing ± NGS/PCR.@OncoAlert.
ejcancer.com
Immune checkpoint inhibitors (ICIs) significantly improve survival in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI) tumors. In 2022, ICIs were approved as...
0
5
12
En países IDH alto 🇪🇺🇺🇸 el enfoque ya cambió:.✅Vacunar (niños y niñas) contra VPH para prevenir cáncer orofaríngeo. En 🇲🇽, seguimos c/cifras alarmantes de cáncer cervicouterino. Excelente video @NEJM sobre a quién vacunar, por qué, cuanto… spoiler.
0
1
4
RT @LizzySmyth1: Very pleased to share this review on FGFR2b which is a key emerging biomarker in gastric and gastroesophageal #Cancer. Loo….
0
21
0
RT @DrSamuelBHume: There's been amazing progress against liver cancer over the last 60 years. (Specifically, hepatocellular carcinoma treat….
0
28
0
RT @CACancerJournal: Revisit this 2024 review by @VivekSubbiah et al which maps current FDA approvals, patient perspectives, and what’s ahe….
0
44
0
RT @OncoAlert: Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study . .
0
13
0
Sex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis
jamanetwork.com
This cohort study assesses whether there are differences in the risk of adverse liver events between male and female patients with cirrhosis.
0
0
0
Sex disparities in cirrhosis @JAMA_current (n=438,706).🔴Men.↑ ALD🥂, HCV, HBV.↑ HCC (HR 2.1), transplant (HR 1.63), decomp. cirr. (HR 1.16).🟠Women.↑ MASLD, autoimmune & cryptogenic. Male sex = strong predictor of HCC in all etiologies
1
1
2
RT @Onco_Cifu88: 🚨 Common sense in HCC trials:.Is PFS always a meaningful endpoint?.Not really. If progression-free survival doesn’t transl….
0
11
0
RT @WilliamAird4: Ever wonder why bruises change color? . Red → Blue → Green → Yellow → Brown. That’s hemoglobin breaking down:. 🔴 Oxy Hb →….
0
109
0
3/3.🔺65% with low AMH conceived, often without ART. 🔺Limitations: no baseline AMH, no male factor data. 🔺Fertility counseling should include but not be limited by AMH.
0
1
4
2/3.48%: AMH <0.5 ng/mL.🔺11%: premature ovarian insufficiency (all after chemo).🔺OR 0.52: ↓ pregnancy odds with low AMH.🔺OR 1.07: FSH at 3 mo predicted ovarian insufficiency.✅ ET type/duration? No impact on fertility.
1
1
4
🧵POSITIVE trial changes how we counsel young HR+ Breast cancer pts. ✅74% conceived after pausing endocrine therapy, 65% even with AMH <0.5 ng/mL. 🤰Low ovarian reserve ≠ No chance. 📉 LOR was the strongest predictor of reduced fertility.1/3.@OncoAlert
2
28
73
RT @StephenVLiu: Available @JTOonline - the 2024 @IASLC Global Survey on Biomarker Testing. Majority (67%) reported most patients had bioma….
jto.org
Biomarker status is vital to inform optimal care for individuals with lung cancer, yet implementation of testing has been sub-optimal due to cost, lack of quality and standards, access, awareness,...
0
29
0
RT @Ecastromarcos: Our last paper in @Annals_Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater….
0
34
0
Gene expression profiling in breast cancer brain mets. Among matched pairs, 42% lost ER, 55% lost PR, 45% gained HER2 & 42% acquired a basal-like phenotype. BM showed ↓luminal markers & ↑immune genes, revealing molecular divergence from the primaries.
1
19
42
RT @DFCI_BreastOnc: The FDA granted breakthrough therapy designation to first-line treatment with trastuzumab deruxtecan (Enhertu) plus per….
0
33
0
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. @NEJM 2025 . Tarlatamab, a DLL3-targeted BiTE, showed mOS of 14.3 mo in SCLC post 1L chemo +/- ICI, offering benefit in this aggressive, hard to treat setting.
0
15
74
RT @OncoAlert: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis . https:/….
0
22
0